This disclosure provides a novel lyophilized formulation that incorporates a surfactant solution to stabilize the Sabin inactivated polio vaccine and demonstrate the vaccine efficacy in an in vivo challenge model. Furthermore, SE-HPLC analysis of D-antigen content in in inactivated polio vaccine can be used to provide a method for high throughput evaluation of inactivated poliovirus stability.